Open AccessMulticenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs. standard follow-up in surgical resectable HNSCC after adjuvant therapy
Author(s) -
CS Betz,
Mascha Binder,
Adrian Münscher,
Carola Busch
Publication year - 2019
Publication title -
laryngo-, rhino-, otologie
Language(s) - English
Resource type - Conference proceedings
eISSN - 1438-8685
pISSN - 0935-8943
DOI - 10.1055/s-0039-1685965
Subject(s) - nivolumab , medicine , ipilimumab , immunotherapy , adjuvant , oncology , head and neck squamous cell carcinoma , maintenance therapy , adjuvant therapy , radiation therapy , randomized controlled trial , head and neck cancer , chemotherapy , cancer